🔗 Share this article

While the US undertakes unprecedented changes to its immunization recommendations, an unexpected name has surfaced somewhat surprisingly: Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who rose to prominence by questioning coronavirus shots throughout the pandemic and has focused upon alleged deaths after Covid immunization in her short time at the Food and Drug Administration.

Proposed Shifts to Childhood Vaccine Program

Public health authorities were set to reveal sweeping revisions to the pediatric vaccination calendar in December, synchronizing the US with the Danish national calendar, sources say – a significant shift that would place the US out of alignment with a large portion of the global community with insufficient data for benefit. This reveal has been postponed until the coming year.

Instead of the top vaccines chief, Høeg is listed to address the audience at the event. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the office this year.

Consolidating Power at the FDA

Høeg's temporary position might represent a closer partnership between the drug and vaccine divisions as Høeg and Dr. Prasad consolidate power at the FDA – and it points to a greater focus upon reevaluating already-approved vaccines at the FDA.

The new acting director has often pushed for discontinuing specific pediatric vaccine recommendations in the US to become more in line with Denmark's approach, a country with universal health coverage and a citizenry roughly the size of Wisconsin’s.

So far public appearances, she has persisted in emphasizing on vaccination policy – typically the purview of Dr. Prasad, head of the FDA’s CBER – as opposed to drug regulation.

Concerns Over Background

The appointee has little discernible background in medication creation, approval processes or management, which has been standard for previous leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the commissioner and the vaccine center since March.

“She appears not to have any of the qualifications” for leading the drug-regulation department, stated a neurologist and psychiatrist. “She lacks experience running a clinical trial. She lacks experience in leading a large organization. She lacks background in drug approvals.”

Past commissioners of the center would “grasp legal statutes and the underlying principles of pharmaceutical innovation”, commented a former acting FDA commissioner. “Frankly, she doesn’t have the kind of background that former directors who led the center have had.”

The drug center has an vast range of responsibilities at the FDA, the former commissioner pointed out.

“The public just pays attention on the new drug program, but the generic program clears thousands of generic drugs. There’s a biologic copycat branch, over-the-counter program and more, and each of these must be managed,” she explained. “The area you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a major leadership element to the job, which supervises in excess of 5,000 personnel. “It’s a huge administrative position, if you perform it correctly,” the former official said.

Response and Contentious Policies

Regarding inquiries about Dr. Høeg's qualifications and whether this appointment indicates increased cooperation among regulatory chiefs on immunizations, a spokesperson said that the “concerns stem from inaccurate presumptions”.

“Her resume matches the functions of her position,” the representative said, pointing to the time Dr. Høeg spent counseling the agency head on “medication safety and approval science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's controversial expedited review system, a disputed rapid drug-approval program that allegedly troubled her predecessors. “How are these therapies being selected for this voucher program? Who is making the choices?” Howard said. “There’s a lot of confidentiality going on at the regulatory body right now.”

Broadly speaking, he stated, “the agency looks to be trending towards laxer rules of all drugs, aside from immunizations.”

Established History on Immunizations

With vaccines, Høeg has a more documented, if problematic, past, some experts observe. She authored a analysis using unconfirmed public submissions to assess the frequency of myocarditis after COVID-19 vaccination. She consulted for the Florida top health official Joseph Ladapo, who was said to have changed statistics to imply COVID-19 vaccines are pose a greater threat than they are.

Among her “desired changes” for the new federal leadership included revising guidelines for recently developed shots and halting “unnecessary” vaccines, she remarked following the vote on a online show. At the FDA, Dr. Høeg has allegedly floated the idea of excluding teenage boys from receiving COVID-19 vaccinations.

“She’s an complete dogmatist who commences with her beliefs and reverse-engineers to accommodate the science in a extremely misleading, fraudulent way,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Høeg became part of fellow dissenters, {like|